Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer globally, accounting for 20% of all skin cancers.
• Immunosuppression is a significant risk factor for cSCC development, disease progression, and mortality.
• Current guidelines acknowledge immunosuppression as a risk factor, but standardized management protocols for these high-risk patients are limited.

Purpose of the Study:

• To review current knowledge on cSCC in immunosuppressed (IS) patients.
• To identify critical knowledge gaps in the evaluation and management of cSCC in IS individuals.
• To highlight recent clinical trials relevant to this patient population.

Main Methods:

• Literature review of existing research on cSCC in IS patients.
• Analysis of current guidelines from NCCN and AJCC.
• Summary of findings from recent clinical trials.

Main Results:

• cSCC is more aggressive and has higher mortality rates in IS patients.
• There is a lack of standardized treatment protocols for IS patients with cSCC.
• Recent trials show promise but require further investigation.

Conclusions:

• Management of cSCC in IS patients presents a significant clinical challenge.
• Dedicated research is crucial to improve outcomes for IS patients with cSCC.
• Further studies and clinical trials are needed to establish evidence-based guidelines.